3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Hepatocellular
7
Leukemia, Myeloid, Acute
5
Neuroblastoma
2
Neoplasm Metastasis
2
Thyroid Neoplasms
1
Sarcoma, Myeloid
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Hepatoblastoma
1
Gastrointestinal Stromal Tumors
1
Fibrolamellar hepatocellular carcinoma
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
pembrolizumab
2
omipalisib
2
larotrectinib
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tipifarnib
1
temsirolimus
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Sorafenib
×
90 days
×
Clear all
NCT02185560
2026-04-14
JPMS-DTC
Bayer
Active not recruiting
453 enrolled